IronBridge Capital Management LP decreased its position in shares of Eli Lilly and Company (NYSE:LLY) by 49.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 253,966 shares of the company’s stock after selling 245,064 shares during the period. Eli Lilly and comprises about 1.3% of IronBridge Capital Management LP’s holdings, making the stock its 19th largest position. IronBridge Capital Management LP’s holdings in Eli Lilly and were worth $21,361,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of LLY. UBS Asset Management Americas Inc. boosted its position in Eli Lilly and by 22.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 6,406,387 shares of the company’s stock worth $471,190,000 after buying an additional 1,195,661 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its position in Eli Lilly and by 0.8% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 3,961 shares of the company’s stock worth $291,000 after buying an additional 30 shares during the last quarter. Teachers Advisors LLC boosted its position in Eli Lilly and by 48.9% in the fourth quarter. Teachers Advisors LLC now owns 2,642,094 shares of the company’s stock worth $194,326,000 after buying an additional 868,053 shares during the last quarter. Kentucky Retirement Systems purchased a new position in Eli Lilly and during the fourth quarter worth about $5,185,000. Finally, Kentucky Retirement Systems Insurance Trust Fund purchased a new position in Eli Lilly and during the fourth quarter worth about $2,313,000. Institutional investors and hedge funds own 75.59% of the company’s stock.
Shares of Eli Lilly and Company (NYSE LLY) traded down 0.94% during trading on Friday, hitting $77.07. The stock had a trading volume of 4,061,282 shares. The stock has a market cap of $81.31 billion, a P/E ratio of 33.35 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The stock’s 50 day moving average price is $82.39 and its 200-day moving average price is $81.90.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.86 earnings per share. Analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is currently 90.04%.
TRADEMARK VIOLATION NOTICE: This article was reported by BNB Daily and is the sole property of of BNB Daily. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/eli-lilly-and-company-lly-stake-lowered-by-ironbridge-capital-management-lp-updated-updated-updated.html.
A number of research firms have recently weighed in on LLY. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Friday, August 4th. Sanford C. Bernstein reissued an “outperform” rating and issued a $88.00 target price on shares of Eli Lilly and in a research report on Sunday, May 21st. TheStreet lowered Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. BMO Capital Markets reissued an “underperform” rating and issued a $73.00 target price on shares of Eli Lilly and in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a research note on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $88.27.
In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the transaction, the insider now owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 669,733 shares of company stock valued at $55,845,287. 0.20% of the stock is currently owned by company insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.